Acetylon Pharmaceuticals

Wheeler joins Acetylon

Monday, December 12, 2011

Acetylon Pharmaceuticals has named Catherine A. Wheeler, MD, vice president, clinical development. Wheeler will have responsibility for all clinical development functions of the company, including current and future clinical trials of Acetylon’s HDAC6 selective drug candidate, ACY-1215, in multiple myeloma as well as other potential hematologic and solid tumor disease indications. She will also lead the clinical development of future drug candidates in inflammatory and neurodegenerative diseases.

[Read More]